|
|
SLA-Alum |
|
Vaxjo ID |
193 |
|
Vaccine Adjuvant Name |
SLA-Alum |
|
Adjuvant VO ID |
VO_0006100
|
|
Description |
combination vaccine adjuvant of a synthetic TLR4 agonist and aluminum salt that induces Th1 response |
|
Stage of Development |
Research |
|
Location Licensed |
US (AAHI) |
|
Host Species for Testing |
3 |
|
Components |
aqueous formulation (AF) of a chemically synthesized toll-like receptor (TLR)-4 agonist, second-generation lipid adjuvant (SLA), and a phospholipid excipient that is adsorbed to aluminum hydroxide (Alum) |
|
Storage |
2-8C |
|
Preparation |
For clinical uses, SLA-Alum is formulated by using SLA-AF with an antigen adsorbed to Alum. The antigen may be adsorbed to the Alum before or after adsorption of SLA-AF |
|
Function |
innate immune activation |
| References |
(Soza, 2023): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=82]
Poncet et al., 2020: Poncet D, Hessler C, Liang H, Gautheron S, Sergent M, Rintala ND, Seydoux E, Huang PD, Argilla D, Ruiz S, Heinrichs J, Maciel M Jr, Orr MT. Preclinical optimization of an enterotoxigenic Escherichia coli adjuvanted subunit vaccine using response surface design of experiments. NPJ vaccines. 2020; 5; 83. [PubMed: 32983577].
Van et al., 2016: Van Hoeven N, Joshi SW, Nana GI, Bosco-Lauth A, Fox C, Bowen RA, Clements DE, Martyak T, Parks DE, Baldwin S, Reed SG, Coler RN. A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations. PloS one. 2016; 11(2); e0149610. [PubMed: 26901122].
|
|
